

6th Floor

One London Wall

London

EC2Y 5EB

25 Apr 2007

Dr. Daniel Brasseur

Chairman, Committee for Medicinal Products for Human Use

c/o CHMP Secretariat

European Medicines Agency

7 Westferry Circus

Canary Wharf

London E14 4HB

United Kingdom

Subject: Withdrawal of Vitragan (Hyaluronidase), 1020 IU/ml, powder for solution for injection

EMEA/H/C/000696/000

www.istavision.com

Dear Dr Brasseur

I would like to inform you that, at this point in time, ISTA Pharma Limited has taken the decision to withdraw the application for Marketing Authorisation of Vitragan (Hyaluronidase) 1020 IU/ml, powder for solution for injection, which was intended to be used for the treatment of vitreous hemorrhage, to improve visual acuity and to facilitate the physician's ability to diagnose the underlying retinal pathology.

This withdrawal is based on the request for additional information that cannot be responded to within the timeframe allowed under the Centralised Procedure.

We reserve the right to make further submissions at a future date in this or other therapeutic indication(s).

I agree for this letter to be published on the EMEA website.

Yours sincerely,

ISTA Pharmaceuticals, Inc.